Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell Malignancies

ATLANTA--(BUSINESS WIRE)--Genitope Corporation (NASDAQ:GTOP) today announced results of two pre-clinical studies, which demonstrated the proof of concept of the company’s monoclonal antibody program to treat B-cell malignancies such as non-Hodgkin’s lymphoma (NHL). In these pre-clinical studies, two monoclonal antibodies in development depleted targeted B-cells, without significantly affecting the non-targeted B-cells. The results of these studies were presented this week at the American Society of Hematology 49th Annual Meeting and Exposition.